New device could speed up GERD diagnosis and save billions

NCT ID NCT07227506

Recruiting now Diagnosis Sponsor: Medical College of Wisconsin Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 28, 2026 · Updated 3 times

Summary

This study tests a new FDA-approved device called MuVI that measures electrical resistance in the esophagus to diagnose GERD and eosinophilic esophagitis. Researchers will enroll 50 adults with chronic esophageal symptoms who are already scheduled for an upper endoscopy. The goal is to see if this device can diagnose these conditions more accurately and cost-effectively than current methods, potentially reducing the need for multiple procedures.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MuVI Esophageal mucosal impedance testing device
What this could lead to: If successful, this device could provide a faster, cheaper, and more accurate way to diagnose GERD and eosinophilic esophagitis, reducing the need for multiple procedures.
What could go wrong: This is a small early study with only 50 participants, so results may not apply to everyone. The device may not be more accurate than current tests.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EOSINOPHILIC ESOPHAGITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

eosinophilic esophagitis gastroesophageal reflux disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EOSINOPHILIC ESOPHAGITIS GERD

Contacts and locations

Locations

Froedtert Hospital
RECRUITING

Milwaukee, Wisconsin, 53226, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.